Suppr超能文献

甲状腺眼病患者中性粒细胞与淋巴细胞比值与临床及影像学参数的相关性

The correlation of the neutrophil-lymphocyte ratio to clinical and imaging parameters in patients with thyroid eye disease.

作者信息

Zhang Xiaowen, Han Chen, Wang Hongwei, Sun Xinghong, Dou Xin, He Xueying, Wu Di, Shen Shanmei, Zhu Dalong, Zhang Xinlin, Bi Yan

机构信息

Department of Endocrinology, Drum Tower Hospital affiliated to Nanjing University Medical School, Branch of National Clinical Research Centre for Metabolic Diseases, Endocrine and Metabolic Disease Medical Center, Drum Tower Hospital affiliated to Nanjing University Medical School, Nanjing, China.

Department of Endocrinology and Metabolism, Drum Tower Clinical Medical College, Southeast University, Nanjing, China.

出版信息

Endocr Connect. 2022 Oct 10;11(11). doi: 10.1530/EC-22-0260. Print 2022 Nov 1.

Abstract

Thyroid eye disease (TED) is the major extrathyroidal manifestation of Graves' disease (GD). Treatment choice is based on clinical activity and severity of TED, as evaluated with clinical activity score (CAS) and magnetic resonance (MR) imaging. We aimed to determine the relationship between neutrophil-to-lymphocyte ratio (NLR), a readily available indicator of systemic inflammation, and clinical and MR imaging parameters in TED patients. Eighty-seven consecutive TED patients were included. The average signal intensity ratio (SIR), average extraocular muscle (EOM) diameter, and proptosis of the study eye were extracted from MR images. A baseline NLR ≥ 2.0 was recorded in 37 (42.5%) patients and NLR < 2.0 in 50 (57.5%) patients. TED patients with NLR ≥ 2.0 were older, had a higher CAS, average SIR, average EOM diameter and proptosis, and a lower serum thyrotrophin receptor antibody level than patients with NLR < 2.0 (all P < 0.05). All MR parameters showed significant correlation with CAS (P < 0.05). NLR correlated significantly with CAS (P = 0.001), average SIR (P = 0.004), average EOM diameter (P = 0.007), and proptosis (P = 0.007). Multiple regression revealed a significant correlation between NLR and CAS (P = 0.001), average SIR (P = 0.029), and proptosis (P = 0.037). Cox regression analysis showed that a high NLR at baseline was associated with a worse clinical outcome of TED (hazard ratio 3.7, 95% CI 1.22-11.2, P = 0.02), at a median follow-up of 25 months. In conclusion, NLR was correlated with CAS and MR imaging parameters and was associated with a worse clinical outcome of TED at follow-up in patients with TED. Additional prospective studies are needed to validate our findings.

摘要

甲状腺眼病(TED)是格雷夫斯病(GD)主要的甲状腺外表现。治疗方案的选择基于TED的临床活动度和严重程度,通过临床活动评分(CAS)和磁共振(MR)成像进行评估。我们旨在确定中性粒细胞与淋巴细胞比值(NLR)这一易于获取的全身炎症指标与TED患者临床及MR成像参数之间的关系。纳入了87例连续的TED患者。从MR图像中提取研究眼的平均信号强度比(SIR)、平均眼外肌(EOM)直径和眼球突出度。37例(42.5%)患者记录到基线NLR≥2.0,50例(57.5%)患者NLR<2.0。与NLR<2.0的患者相比,NLR≥2.0的TED患者年龄更大,CAS、平均SIR、平均EOM直径和眼球突出度更高,血清促甲状腺素受体抗体水平更低(所有P<0.05)。所有MR参数均与CAS显著相关(P<0.05)。NLR与CAS(P = 0.001)、平均SIR(P = 0.004)、平均EOM直径(P = 0.007)和眼球突出度(P = 0.007)显著相关。多元回归显示NLR与CAS(P = 0.001)、平均SIR(P = 0.029)和眼球突出度(P = 0.037)之间存在显著相关性。Cox回归分析显示,在中位随访25个月时,基线高NLR与TED更差的临床结局相关(风险比3.7,95%CI 1.22 - 11.2,P = 0.02)。总之,NLR与CAS和MR成像参数相关,且在TED患者随访中与更差的临床结局相关。需要进一步的前瞻性研究来验证我们的发现。

相似文献

2
Mycophenolate Mofetil (CellCept®) in Combination With Low Dose Prednisolone in Moderate to Severe Graves' Orbitopathy.
Front Med (Lausanne). 2022 Feb 11;9:788228. doi: 10.3389/fmed.2022.788228. eCollection 2022.
3
Early experience with teprotumumab for chronic thyroid eye disease.
Am J Ophthalmol Case Rep. 2020 May 15;19:100744. doi: 10.1016/j.ajoc.2020.100744. eCollection 2020 Sep.
4
Inflammatory Markers in Thyroid Eye Disease: A Meta-Analysis.
Endocr Res. 2024 Aug-Nov;49(4):193-202. doi: 10.1080/07435800.2024.2362787. Epub 2024 Jun 13.
7
Knowledge of Thyroid Eye Disease in Graves' Disease Patients With and Without Orbitopathy.
Thyroid. 2019 Apr;29(4):557-562. doi: 10.1089/thy.2018.0665. Epub 2019 Mar 22.
8
Evaluation of thyroid eye disease: quality-of-life questionnaire (TED-QOL) in Korean patients.
Can J Ophthalmol. 2014 Apr;49(2):167-73. doi: 10.1016/j.jcjo.2013.12.007.
10
Thyroid eye disease presenting with superior rectus/levator complex enlargement.
Orbit. 2020 Feb;39(1):5-12. doi: 10.1080/01676830.2019.1594969. Epub 2019 May 6.

引用本文的文献

2
The role of IL-6 in thyroid eye disease: an update on emerging treatments.
Front Ophthalmol (Lausanne). 2025 Apr 14;5:1544436. doi: 10.3389/fopht.2025.1544436. eCollection 2025.

本文引用的文献

2
Serum Inflammation-based Scores in Endocrine Tumors.
J Clin Endocrinol Metab. 2021 Sep 27;106(10):e3796-e3819. doi: 10.1210/clinem/dgab238.
4
Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease.
Br J Ophthalmol. 2022 Feb;106(2):165-171. doi: 10.1136/bjophthalmol-2020-317806. Epub 2020 Nov 10.
5
Management of Graves Thyroidal and Extrathyroidal Disease: An Update.
J Clin Endocrinol Metab. 2020 Dec 1;105(12):3704-20. doi: 10.1210/clinem/dgaa646.
6
Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves' orbitopathy.
J Endocrinol Invest. 2021 Mar;44(3):581-585. doi: 10.1007/s40618-020-01353-y. Epub 2020 Jul 9.
7
Inflammatory biomarkers and dynamics of neutrophil-to-lymphocyte ratio in anaplastic thyroid carcinoma.
Endocrine. 2020 Oct;70(1):115-122. doi: 10.1007/s12020-020-02313-5. Epub 2020 Apr 19.
8
Teprotumumab for the Treatment of Active Thyroid Eye Disease.
N Engl J Med. 2020 Jan 23;382(4):341-352. doi: 10.1056/NEJMoa1910434.
9
Role of a new bioassay for thyroid-stimulating antibodies (aequorin TSAb) in Graves' ophthalmopathy.
Endocr J. 2020 Mar 28;67(3):347-352. doi: 10.1507/endocrj.EJ19-0398. Epub 2019 Dec 10.
10
High neutrophil-to-lymphocyte ratio is associated with relapse in Graves' disease after antithyroid drug therapy.
Endocrine. 2020 Feb;67(2):406-411. doi: 10.1007/s12020-019-02137-y. Epub 2019 Nov 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验